针对性治疗和高级非状非小细胞肺癌患者的存活率 - 全国范围和纵向研究
Johanne Elise Nyen1, Anja Ødegård Booth2, Øyvind Husby2
1Oslo Economics, Oslo, Norway.
Frontiers in oncology
|March 7, 2025
概括
这项研究分析了挪威高级非状NSCLC患者的治疗模式和存活率. 与临床试验相比,向疗法显示整体存活率有所改善,尽管治疗时间较短.
科学领域:
- 在瘤学瘤学.
- 胸部瘤学 胸部瘤学
- 在癌症治疗中的基因组学.
背景情况:
- 具有特定基因变异 (EGFR+,ALK+,ROS1+) 的高级非状非小细胞肺癌 (NSCLC) 需要量身定制的治疗策略.
- 了解现实世界治疗模式,治疗时间 (ToT) 和整体存活率 (OS) 对于优化挪威护理至关重要.
研究的目的:
- 描述挪威高级非状,EGFR+,ALK+和ROS1+NSCLC患者的治疗模式,ToT和OS.
- 评估与诊断期和向治疗利用有关的生存趋势.
主要方法:
- 在2015-2022年期间,对5279名被诊断患有晚期非状NSCLC的患者进行了回顾性分析.
- 来自挪威癌症登记处,挪威患者登记处和挪威处方药登记处的数据.
- 从分别治疗开始/收集和诊断日期计算的ToT和OS.
主要成果:
- 在EGFR+ (75%),ALK+ (88%) 和ROS1+ (58%) 患者中,在三个月内开始全身治疗的高率.
- 一线中位数的ToT因药物而异:欧西默蒂尼布 (11个月) 治疗EGFR+;阿莱克提尼布 (20个月) 治疗ALK+;克里佐替尼布 (5个月) 治疗ROS1+.
- 2020-2022年诊断的患者的未调整中位数OS (23个月) 与2015-2019年 (19个月) 诊断的患者相比显著更高.
结论:
- 虽然在临床试验中,针对性治疗的治疗时间比无进展生存时间短,但患者从改善的整体生存时间中受益.
- 现实数据表明,在研究期间,在NSCLC中具有可向基因组改变的患者中,存活率呈积极趋势.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.4K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:21Cancer Survival Analysis
318
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
318